Barrington analyst Michael Petusky maintained a Buy rating on Haemonetics (NYSE:HAE) Corp. on Thursday, setting a price target of $68, which is approximately 9.73% above the present share price of $61.97.
Petusky expects Haemonetics Corp . to post earnings per share (EPS) of -$0.22 for the third quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Haemonetics, with an average price target of $79.83.
The analysts price targets range from a high of $90 to a low of $68.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $225.03 million and a net profit of -$21.37 million. The company's market cap is $3.16 billion.
According to TipRanks.com, Barrington analyst Michael Petusky is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 11.3% and a 54.98% success rate.
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following geographical segments: Japan, EMEA (Europe, the Middle East, and Africa), North America Plasma, and All Other. Its products include surgical and diagnostic devices, blood and plasma center devices, blood center software, hospital software, and plasma center software. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Braintree, MA.